| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/15/2006 | US20060127420 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof |
| 06/15/2006 | US20060127418 Composition containing Leishmania Lip2a |
| 06/15/2006 | US20060127395 comprising an E25 anti-IgE antibody and acetic acid ; nasal sprays and slow release formulations drying or freeze-drying; treating an allergic disease |
| 06/15/2006 | US20060127386 Antioxidant polymer nanocarriers for use in preventing oxidative injury |
| 06/15/2006 | US20060127326 Oral hygiene product for human and animal use with a melatonin base as an active product |
| 06/15/2006 | US20060127324 Chewable oral compositions containing an anti-microbial agent and methods of formulating the compositions to have acceptable germ kill properties and taste |
| 06/15/2006 | US20060127323 Formoterol and ciclesonide combination |
| 06/15/2006 | US20060127322 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols |
| 06/15/2006 | US20060127321 Pharmaceutical foam |
| 06/15/2006 | US20060127320 Method of delivering parathyroid hormone to a human |
| 06/15/2006 | US20060127319 dosage form of a mixture of drugs, foaming agents and gases, having improved pharmacokinetics; drug delivery systems |
| 06/15/2006 | US20060127317 Nasallly applicable pharmaceutical preparation and the production thereof |
| 06/15/2006 | US20060127310 Amplification of biotin-mediated targeting |
| 06/15/2006 | US20060127307 Devices and compositions containing boron and silicon for use in neutron capture therapy |
| 06/15/2006 | US20060124695 Stable liquid preparation |
| 06/15/2006 | US20060124125 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume |
| 06/15/2006 | CA2594103A1 Medicament for hygienic application inside the ear |
| 06/15/2006 | CA2591203A1 Topical drug delivery system |
| 06/15/2006 | CA2590277A1 Product containing prostaglandin having fluorine atom in its molecule |
| 06/15/2006 | CA2590136A1 Compositions and methods for treating conditions of the nail unit |
| 06/15/2006 | CA2589656A1 Stable compositions of fenofibrate with fatty acid esters |
| 06/15/2006 | CA2588905A1 Topical skin patch containing xanthophylls |
| 06/15/2006 | CA2587516A1 Treatment and prevention of epilepsy |
| 06/15/2006 | CA2586597A1 Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form |
| 06/15/2006 | CA2586288A1 Oral suspension comprising meloxicam |
| 06/14/2006 | EP1669374A1 Method for forming aqueous secondary dispersions of water insoluble polymers |
| 06/14/2006 | EP1669092A1 Preparation for the prophylaxis of restenose |
| 06/14/2006 | EP1669091A2 Therapeutic inhibitor of vascular smooth muscle cells |
| 06/14/2006 | EP1669090A1 Bitterness-masking particulate jelly beverage |
| 06/14/2006 | EP1669087A1 Preparation containing basic drug |
| 06/14/2006 | EP1669082A1 Dried extract from inflammatory rabbit skin inoculated with vaccinia virus and process for its manufacture |
| 06/14/2006 | EP1669081A1 Apoptotic entities for use in treatment of T-cell-mediated und inflammatory disorders |
| 06/14/2006 | EP1669078A1 Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside RB 1 |
| 06/14/2006 | EP1669075A1 Therapeutic agent for ageing macular degeneration |
| 06/14/2006 | EP1669073A2 Fulvestrant formulation |
| 06/14/2006 | EP1669066A1 Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient |
| 06/14/2006 | EP1669065A1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
| 06/14/2006 | EP1669063A1 Transdermal therapeutic systems for administering rotigotine |
| 06/14/2006 | EP1669062A1 Extended release indapamide tablets and their process of manufacture |
| 06/14/2006 | EP1668424A2 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 06/14/2006 | EP1668358A1 Reconstitution medium for protein and peptide formulations |
| 06/14/2006 | EP1668062A2 Telechelic homopolyamino acids functionalized by hydrophobic groups and uses, particularly therapeutic, thereof |
| 06/14/2006 | EP1667960A1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 06/14/2006 | EP1667790A1 Device and method for making particles |
| 06/14/2006 | EP1667742A1 Disinfectant, antibiotic and anesthetic containing device |
| 06/14/2006 | EP1667723A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 06/14/2006 | EP1667709A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 06/14/2006 | EP1667703A2 A composition and method of treatment for urogenital conditions |
| 06/14/2006 | EP1667696A1 Probiotic storage and delivery |
| 06/14/2006 | EP1667693A1 Compositions and methods of using lamellar bodies for therapeutic purposes |
| 06/14/2006 | EP1667687A1 Pulmonary disease treatment |
| 06/14/2006 | EP1667681A1 A novel transmucosal delivery system |
| 06/14/2006 | EP1667667A2 Hydrogel compositions with an erodible backing member |
| 06/14/2006 | EP1667666A1 Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
| 06/14/2006 | EP1667665A1 Capsules comprising drug-loaded pellets with different release profiles |
| 06/14/2006 | EP1667664A1 Coated tablets |
| 06/14/2006 | EP1667663A1 Osmotic dosage forms for controlled delivery of alprazolam |
| 06/14/2006 | EP1667662A1 Buccal drug delivery |
| 06/14/2006 | EP1667661A1 Extended release formulation of beta-lactam antibiotics |
| 06/14/2006 | EP1667660A2 Pantoprazole multiparticulate formulations |
| 06/14/2006 | EP1667659A1 Injectable, oral, or topical sustained release pharmaceutical formulations |
| 06/14/2006 | EP1667658A2 Granular sustained release preparation and production thereof |
| 06/14/2006 | EP1667657A1 Topical aerosol foams |
| 06/14/2006 | EP1667656A1 Compositions and methods for delivery of biologically active agents |
| 06/14/2006 | EP1667655A1 New use, pharmaceutical preparations as well as a process for their production |
| 06/14/2006 | EP1667654A2 Methods for the controlled delivery of pharmacologically active compounds |
| 06/14/2006 | EP1667653A1 Dosage form for controlled release of an active agent formulation |
| 06/14/2006 | EP1667652A2 Improved controlled release dosage form including a banded engine |
| 06/14/2006 | EP1667650A1 Skin care topical ointment |
| 06/14/2006 | EP1667649A2 A dried biotherapeutic composition, uses, and device and methods for administration thereof |
| 06/14/2006 | EP1667633A2 Polysaccharides for pulmonary delivery of active agents |
| 06/14/2006 | EP1667622A2 Water dispersible film |
| 06/14/2006 | EP1667619A1 Pharmaceutical delivery system |
| 06/14/2006 | EP1667533A1 Improved formulation for providing an enteric coating material |
| 06/14/2006 | EP1587514B1 A rapid-acting pharmaceutical composition |
| 06/14/2006 | EP1501484B1 A process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose |
| 06/14/2006 | EP1496951B1 Wound dressings comprising an oxidoreductase enzyme in hydrated condition |
| 06/14/2006 | EP1476136B1 Pharmaceutical composition comprising n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process for preparing thereof comprising dry granulation |
| 06/14/2006 | EP1438076B1 Radiopharmaceutical agent for the treatment of early stage cancer |
| 06/14/2006 | EP1401500A4 Nucleotide compounds that block the bitter taste of oral compositions |
| 06/14/2006 | EP1372693B1 Peptides for the treatment of wound contracture |
| 06/14/2006 | EP1313457B1 Transdermal therapeutic system for releasing venlafaxine |
| 06/14/2006 | EP1309315B1 Rapidly disintegrating oral formulation of valdecoxib |
| 06/14/2006 | EP1289475B1 Water-thin emulsions with low emulsifier levels |
| 06/14/2006 | EP1272236B1 Methods and compositions for treating intervertebral disc degeneration |
| 06/14/2006 | EP1261361B1 Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| 06/14/2006 | EP1248606B1 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 06/14/2006 | EP1248595A4 Multi-step drug dosage forms |
| 06/14/2006 | EP1204360B1 Personal care articles |
| 06/14/2006 | EP1180015B8 Generation of therapeutic microfoam |
| 06/14/2006 | EP1175205B1 Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| 06/14/2006 | EP1143963B1 Multiparticulate bisoprolol formulation |
| 06/14/2006 | EP1102742B1 Compounds and compositions for delivering active agents |
| 06/14/2006 | EP1069890B1 Incorporation of active substances in carrier matrixes |
| 06/14/2006 | EP1003551B1 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant |
| 06/14/2006 | EP0951228B1 Disposable pad and method |
| 06/14/2006 | EP0934593B1 Electrically conductive adhesive hydrogels |
| 06/14/2006 | EP0928135B1 System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
| 06/14/2006 | EP0879035B1 Bismuth-containing compositions in topical dosage forms |
| 06/14/2006 | DE19646836B4 Zubereitung, bestehend aus einer flächenhaften, film- oder oblatenartigen Darreichungsform Preparation consisting of a planar, film or wafer-like dosage form |